Cancer Research UK logo.
SearchDonate
  • Search

A trial comparing different ways of deciding on treatment after surgery for breast cancer (MINDACT)

Overview

Cancer types:

Breast cancer

Status:

Results

Phase:

Phase 3

Details

This trial looked at whether a group of 70 genes could help doctors work out who needed to have more treatment after surgery for breast cancer.

It is also looked at different:

  • combination of chemotherapy drugs (with or without an ) for women who were at high risk of breast cancer coming back

  • types of hormone therapy for women who had hormone receptor positive breast cancer

Cancer Research UK supported this trial.

People could join between 2008 and 2011. The team published results in 2013 and 2021.

Recruitment start: 1 May 2008

Recruitment end: 8 July 2011

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Alastair M Thompson

Supported by

Cancer Research UK

Breast International Group

Experimental Cancer Medicine Centre (ECMC)

European Organisation for Research and Treatment of Cancer (EORTC)

NIHR Clinical Research Network: Cancer

Grant Simpson Trust

Other information

This is Cancer Research UK trial number CRUK/07/018.

Last reviewed: 07 Aug 2017

CRUK internal database number: 819

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Find a Clinical Trial

Search our clinical trials database for all cancer trials and studies recruiting in the UK.

An icon of two speech bubbles, indicating a conversation.

Cancer Chat forum

Connect with other people affected by cancer and share your experiences.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.